PE20051173A1 - Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 - Google Patents

Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3

Info

Publication number
PE20051173A1
PE20051173A1 PE2005000205A PE2005000205A PE20051173A1 PE 20051173 A1 PE20051173 A1 PE 20051173A1 PE 2005000205 A PE2005000205 A PE 2005000205A PE 2005000205 A PE2005000205 A PE 2005000205A PE 20051173 A1 PE20051173 A1 PE 20051173A1
Authority
PE
Peru
Prior art keywords
compounds
methyl
hexans
dopamine
modulators
Prior art date
Application number
PE2005000205A
Other languages
English (en)
Inventor
Luca Arista
Giorgio Bonanomi
Federica Damiani
Gabriella Gentile
Fabrizio Micheli
Silvia Terreni
Luca Tarsi
Dieter Hamprecht
Fabio Romano Di
Giovanna Tedesco
Anna Maria Capelli
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20051173A1 publication Critical patent/PE20051173A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS AZABICICLICO(3.1.0) HEXANOS DE FORMULA (I), DONDE G ES FENILO, PIRIDILO, BENZOTIAZOLILO, ENTRE OTROS; p ES 0 A 5; R1 ES HALOGENO, HIDROXI, CIANO, HALOALQUILO(C1-C4), ALCOXI(C1-C4), HALOALCOXI(C1-C4), ENTRE OTROS; R2 ES H O ALQUILO(C1-C4); R3 ES ALQUILO(C1-C4); R4 ES H, FENILO, HETEROCICLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE 5-[5-({3-[(1R,5S/1S,5R)-1-(4-METOXIFENIL)-3-AZABICICLO[3.1.0]HEX-3-IL]PROPIL}TIO)-4-METIL-4H-1,2,4-TRIAZOL-3-IL]-2-METILQUINOLINA, CLORHIDRATO DE 5-[5-({3-[(1R,5S/1S,5R)-1-(4-BROMOFENIL)-3-AZABICICLO[3.1.0]HEX-3-IL]PROPIL}TIO)-4-METIL-4H-1,2,4-TRIAZOL-3-IL]-2-METILQUINOLINA, CLORHIDRATO DE 2-METIL-5-[4-METIL-5-({3-[(1R,5S/1S,5R)-1-FENIL-3-AZABICICLO[3.1.0]HEX-3-IL]PROPIL}TIO)-4H-1,2,4-TRIAZOL-3-IL]QUINOLINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE DOPAMINA D3, Y SON UTILES PARA TRATAR DROGODEPENDENCIAS O COMO AGENTES ANTIPSICOTICOS
PE2005000205A 2004-02-23 2005-02-21 Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 PE20051173A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds

Publications (1)

Publication Number Publication Date
PE20051173A1 true PE20051173A1 (es) 2006-02-14

Family

ID=34890800

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000205A PE20051173A1 (es) 2004-02-23 2005-02-21 Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3

Country Status (26)

Country Link
US (3) US7855298B2 (es)
EP (3) EP2060570B1 (es)
JP (1) JP4960217B2 (es)
KR (1) KR101143718B1 (es)
CN (1) CN1946714B (es)
AR (1) AR047890A1 (es)
AT (3) ATE520686T1 (es)
AU (2) AU2005215918C1 (es)
BR (1) BRPI0507945A (es)
CA (1) CA2557115C (es)
CY (3) CY1109854T1 (es)
DE (1) DE602005018190D1 (es)
DK (3) DK1745040T3 (es)
ES (2) ES2380990T3 (es)
HK (1) HK1103016A1 (es)
HR (3) HRP20100114T1 (es)
IL (1) IL177184A0 (es)
MA (1) MA28438B1 (es)
NO (1) NO20064309L (es)
PE (1) PE20051173A1 (es)
PL (3) PL1745040T3 (es)
PT (3) PT2070922E (es)
RU (1) RU2434011C2 (es)
SI (3) SI2060570T1 (es)
TW (1) TW200538113A (es)
WO (1) WO2005080382A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380990T3 (es) * 2004-02-23 2012-05-22 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
GB0512099D0 (en) 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
WO2007016155A2 (en) 2005-07-27 2007-02-08 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
JP5237807B2 (ja) * 2005-08-22 2013-07-17 グラクソ グループ リミテッド ドーパミンｄ３受容体の調節因子としてのトリアゾール誘導体
ES2434337T3 (es) * 2006-04-03 2013-12-16 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
EP2007751B1 (en) * 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
WO2007113258A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
GB0607899D0 (en) * 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719235D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
CN102131813B (zh) 2008-06-24 2014-07-30 科德克希思公司 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
KR20130105914A (ko) 2008-09-22 2013-09-26 카이맨 케미칼 컴파니 인코포레이티드 Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
EP2445887B1 (en) 2009-06-26 2014-11-05 Panacea Biotec Limited Novel azabicyclohexanes
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP3068226A4 (en) * 2013-11-11 2017-05-17 Euthymics Bioscience, Inc. Novel methods
US10273244B2 (en) * 2015-08-05 2019-04-30 Indivior Uk Limited Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
CA3187566A1 (en) 2020-06-22 2021-12-30 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
AU2022421212A1 (en) * 2021-12-21 2024-07-04 Corcept Therapeutics Incorporated Bicyclic indazole glucocorticoid receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
CN1254474C (zh) * 2000-11-14 2006-05-03 史密斯克莱·比奇曼公司 作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
KR100621292B1 (ko) 2001-10-22 2006-09-13 화이자 프로덕츠 인코포레이티드 오피오이드 수용체 길항제로서의3-아자비사이클로[3.1.0]헥산 유도체
PL375256A1 (en) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
ES2380990T3 (es) * 2004-02-23 2012-05-22 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) * 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
JP5237807B2 (ja) * 2005-08-22 2013-07-17 グラクソ グループ リミテッド ドーパミンｄ３受容体の調節因子としてのトリアゾール誘導体
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
ES2434337T3 (es) * 2006-04-03 2013-12-16 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
AU2009212887A1 (en) 2009-09-24
US20070142438A1 (en) 2007-06-21
DE602005018190D1 (de) 2010-01-21
CN1946714A (zh) 2007-04-11
DK2070922T3 (da) 2011-11-28
EP1745040A1 (en) 2007-01-24
KR20060127991A (ko) 2006-12-13
SI2070922T1 (sl) 2011-12-30
RU2006133909A (ru) 2008-03-27
TW200538113A (en) 2005-12-01
PT2070922E (pt) 2011-11-24
US7855298B2 (en) 2010-12-21
AU2005215918B2 (en) 2009-06-11
MA28438B1 (fr) 2007-02-01
CY1113029T1 (el) 2016-04-13
ES2380990T3 (es) 2012-05-22
EP2070922A1 (en) 2009-06-17
US8283474B2 (en) 2012-10-09
IL177184A0 (en) 2006-12-10
HK1103016A1 (en) 2007-12-14
ATE542816T1 (de) 2012-02-15
PT1745040E (pt) 2010-03-08
EP1745040B1 (en) 2009-12-09
ATE451364T1 (de) 2009-12-15
BRPI0507945A (pt) 2007-07-24
US20100152195A1 (en) 2010-06-17
WO2005080382A1 (en) 2005-09-01
DK1745040T3 (da) 2010-04-12
US8263782B2 (en) 2012-09-11
DK2060570T3 (da) 2012-04-30
EP2060570A3 (en) 2009-06-03
PT2060570E (pt) 2012-05-07
AU2005215918C1 (en) 2010-01-21
EP1745040B9 (en) 2010-06-02
CA2557115A1 (en) 2005-09-01
EP2070922B1 (en) 2011-08-17
PL2070922T3 (pl) 2012-01-31
AU2005215918A1 (en) 2005-09-01
HRP20100114T1 (hr) 2010-04-30
EP2060570B1 (en) 2012-01-25
CY1112011T1 (el) 2015-11-04
EP2060570A2 (en) 2009-05-20
CY1109854T1 (el) 2014-09-10
CN1946714B (zh) 2011-06-15
JP4960217B2 (ja) 2012-06-27
NO20064309L (no) 2006-11-23
KR101143718B1 (ko) 2012-07-05
HRP20110781T1 (hr) 2011-11-30
SI1745040T1 (sl) 2010-04-30
CA2557115C (en) 2012-10-02
PL1745040T3 (pl) 2010-05-31
HRP20120281T1 (hr) 2012-04-30
PL2060570T3 (pl) 2012-06-29
SI2060570T1 (sl) 2012-05-31
ATE520686T1 (de) 2011-09-15
RU2434011C2 (ru) 2011-11-20
ES2337590T3 (es) 2010-04-27
AR047890A1 (es) 2006-03-01
US20100160336A1 (en) 2010-06-24
JP2007523208A (ja) 2007-08-16

Similar Documents

Publication Publication Date Title
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20080730A1 (es) Derivados de fenilo como moduladores del receptor s1p
RU2439068C2 (ru) Модуляторы mglur5
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20142099A1 (es) Derivados de sulfonamida
PE20121510A1 (es) Isoquinolinonas y quinazolinonas sustituidas
PE20091925A1 (es) Derivados de indazol sustituidos con fenilo o benzodioxinilo
PE20080065A1 (es) Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
PE20141375A1 (es) Activadores de glucoquinasa
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20080858A1 (es) Compuestos de n-aril pirazol y composiciones que los contienen
PE20110806A1 (es) Compuestos derivados de benzofurano activos contra el virus de la hepatitis c
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20121058A1 (es) Compuestos que modulan el receptor de androgenos
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
PE20091473A1 (es) Heterociclos como inhibidores de esteaoril-coa desaturasa
PE20090592A1 (es) Nuevos derivados de piperazina-amida
PE20070355A1 (es) Antagonistas de cgrp seleccionados y procedimientos para su preparacion
PE20081496A1 (es) Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed